Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results

Key Points

This research aims to evaluate the effectiveness and safety of the anti-CD33 monoclonal antibody BI 836858 combined with azacitidine in older patients with acute myeloid leukemia (AML).
Phase Ib/II trial conducted on older patients with untreated acute myeloid leukemia
Intervention involved the use of BI 836858 alongside azacitidine
Assessments focused on safety and therapeutic responses
Combination therapy improved response rates in older patients with untreated AML
Safety profile was consistent with prior studies of azacitidine-related treatments
Encouraging outcomes warrant further investigation into treatment efficacy

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Evaluates anti-CD33 therapy with azacitidine in older acute myeloid leukemia patients, suggesting potential treatment benefits.

No takes yet. Share an insight, caveat, or question.

Hochman et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share